

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 11, 2024



STRATA SKIN SCIENCES, INC.

(Exact Name of Registrant Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-51481
(Commission File Number)

13-3986004
(I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
(Address of Principal Executive Offices)

19044
(Zip Code)

Registrant's telephone number, including area code: 215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

Item 7.01. Regulation FD Disclosure.

On December 11, 2024, STRATA Skin Sciences, Inc. (the "Company") posted an investor presentation to its website at <https://strataskin sciencesinc.ecs-web.com/>. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following presentation is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be "filed":

<u>Exhibit No.</u>	<u>Exhibit Description</u>
99.1	Investor Presentation dated December 11, 2024, issued by Strata Skin Sciences, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STRATA SKIN SCIENCES, INC.

Date: December 11, 2024

By: /s/ John Gillings
John Gillings
Vice President Finance (Principal Financial Officer
and Principal Accounting Officer)



STRATA

SKIN SCIENCES

Driving Value in Dermatology

Matching Patients with Clinics for a Win-Win-Win Outcome

Investor Presentation

December 2024

NASDAQ: SSKN

Safe Harbor Statement

This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements regarding continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related to successfully integrating the products and employees of the Company, as well as the ability to ensure continued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments will cause its views to change. The information contained in this presentation speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

About Us

STRATA Skin Sciences is a medical technology company offering advanced medical devices for the in-office treatment of life-altering dermatological conditions.



Leading Global Provider of Dermatology In-Office Medical Procedures



\$38B Market Opportunity Across Psoriasis, Vitiligo, Eczema, and Acne markets



Experienced Management with 20+ Year History in Dermatology Market

Capitalization Table

Stock Symbol	NASDAQ: SSKN
Stock Price (as of 11/26/24)	\$2.96
Shares Outstanding (as of 8/12/24)	4.2M
Market Cap	\$12M
Cash & Equivalents*	\$8.4M
Debt*	\$15.2
Enterprise Value	\$19M
Options*	501,726 @ \$8.36 WAEP
Warrants*	80,000 @ \$8.80 WAEP
Inside Ownership (%)	~39%

* As of 9/30/24

Addressing \$38B Dermatology Market

Psoriasis - \$20.1B¹, Vitiligo - \$1.2B², Eczema - \$11.8B³, Acne - \$5.5B⁴



30M Patients in the U.S.

Psoriasis – 8M / Vitiligo - 5M / Eczema - 18M

TheraClear X
ACNE THERAPY SYSTEM



50M+ Acne Patients in the U.S.

- 1) Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected
- 2) Fortune Business Insights Market Report 2018; 2015-2017 historical, 2018 base year, 2019-2026 projected
- 3) Market Data Forecast Analysis Report 2020; 2020 base year, 2021-2026 projected
- 4) Strata Skin Sciences

NASDAQ: SSKN

STRATA
SKIN SCIENCES

Affiliated Academic Institutions

STRATA devices are available at over 50 academic institutes that offer dermatology residency programs



Management Team

Sales and Operational Dermatology Experience



Chief Executive Officer
Dr. Dolev Rafaeli



V.P. Finance
John Gillings



Chief Operating Officer
Shmuel Gov



NASDAQ: SSKN



STRATA Investment Highlights

Unique and Proven Business Model

- Best-in-class Excimer Laser technologies
- Recurring revenue driven by DTC and growing installed base
 - Installed base of 873 XTRAC® domestic devices for Psoriasis, Vitiligo, and Eczema treatments
 - Installed base of 135 TheraClear®X domestic devices for Acne treatments
 - Installed base of ~1700 XTRAC® and VTRAC® devices internationally
- Providing “business in a box” for dermatology practices without an upfront capital spend by practices
- Over 300 peer-reviewed, published clinical studies

A Win-Win-Win Business Model

- For patients – safest, most effective, minimal side effects
- For clinics – stable increased revenue base
- For Payers – the cheapest treatment available

Opportunity for Renewed Growth in U.S. in Recurring Revenue per Device

- Re-emphasis on DTC marketing in U.S. with near-term opportunity of increasing recurring revenue/device by 40%
- More rigorous sales and marketing strategy and process in place
- Both initiatives could collectively grow revenue by double digit percent and help return the company to positive cash flow



3Q24 Financial Highlights

Revenue

- Total revenue \$8.8M (-1% YOY) vs. \$8.9M 3Q23
- Global net recurring revenue \$5.4M (+2% YOY) vs. \$5.3M 3Q23
- Gross domestic XTRAC® recurring billings \$4.8M (-2% YOY) vs. \$4.9M 3Q23
- Revenue per domestic XTRAC® system \$5,332 (+2% YOY) on 873 systems vs. \$5,233 on 929 systems in 3Q23

Gross Margin

- 60.3% (+430 bps YOY) vs. 56.0% in 3Q23

Operating Expenses

- \$5.2M (-7% YOY) (excluding one-time accrual expense) vs. \$5.6M 3Q23

Operating Income

- Non-GAAP operating profit (excluding accrual item) \$128,000
- First time generating positive operating profit since early 2018



Core Domestic Business Model


A True Partnership – A Complete Business Solution



+ **No upfront capital expense**; instead, it's a fee-per-use business model

+ **Complete business solution** includes a suite of value-added support services to maximize practice's success



~900 Partner Dermatology Clinics with 3,000+ Dermatology Providers Across the U.S.



Overview

- 873 Partner XTRAC® clinics + >150 sold XTRAC® devices
- 135 TheraClear®X clinics
- 3 Regions / 23 Sales Territories / 1 National Accounts Manager
- 15 Field Service Techs
- In-house call center and insurance benefits team
- 4 Clinical specialists

Practice Development Program



100 Dermatology, P.L.L.C.
 100 Dermatology, P.L.L.C.
 100 Dermatology, P.L.L.C.
 100 Dermatology, P.L.L.C.

LIVE CLEAR. LIVE FREE.

WHEN THE DIAGNOSIS IS PSORIASIS, THE TREATMENT IS CLEAR. XTRAC.

If you or someone you know has psoriasis, you may have been trying long lasting, effective skin care or over-the-counter treatments to bring itching, scaling, redness and other symptoms of psoriasis under control. XTRAC Clear is a new, non-invasive, prescription-free treatment that offers relief from the painful symptoms of psoriasis. XTRAC Clear is a new, non-invasive, prescription-free treatment that offers relief from the painful symptoms of psoriasis. XTRAC Clear is a new, non-invasive, prescription-free treatment that offers relief from the painful symptoms of psoriasis.

• XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed.

• XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed.

• XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed.

EDMART NEWS

FDA CLEAR

XTRAC

When the diagnosis is **PSORIASIS, VITILIGO or ATOPIC DERMATITIS** the results are clear.

XTRAC Clear

- ✓ XTRAC is safe, pain free with virtually NO SIDE EFFECTS.
- ✓ XTRAC TREATS ANY AREA including hard to treat areas such as scalp, hands, and face.
- ✓ Over 5 MILLION TREATMENTS have been performed worldwide.
- ✓ XTRAC patients see LONG-LASTING BENEFITS.

Don't wait any longer, call us today! **CALL 1-000-000-0000** to Live Clear. XTRAC Clear.

Look Who's Talking About XTRAC

Doctors | **WELLPOINT** | **Bluebird** | **CVS** | **Walgreens**

XTRAC

LIVE CLEAR. LIVE FREE.

When the Diagnosis is Psoriasis, the Treatment is Clear. XTRAC. XTRAC Clear is a new, non-invasive, prescription-free treatment that offers relief from the painful symptoms of psoriasis. XTRAC Clear is a new, non-invasive, prescription-free treatment that offers relief from the painful symptoms of psoriasis. XTRAC Clear is a new, non-invasive, prescription-free treatment that offers relief from the painful symptoms of psoriasis.

• XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed.

• XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed.

• XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed. XTRAC Clear is safe and effective only when used as directed.

NASDAQ: SSKN

- In-Office Patient Education Materials for psoriasis, vitiligo & atopic dermatitis:
 - ✓ Patient Brochures
 - ✓ Counter Cards
 - ✓ In Office Branding
- "Patient-Directed" marketing initiative:
 - ✓ Patient Education Mailings
 - ✓ Outreach Programs
 - ✓ Eblasts

Marketing Support Drives Additional Patient Awareness

- ✓ Patient Eblasts
- ✓ Direct Mailers
- ✓ In-office Branding
- ✓ Social Media
- ✓ Trade Shows
- ✓ Clinical Webinars

TEMPLATE 3

XTRAC
No More Messy Creams

Safe, drug-free treatment for psoriasis

XTRAC LIGHT THERAPY IS A SERIES OF IN-OFFICE TREATMENTS OFFERING:

- ✓ Safe, effective, and gentle for your patients
- ✓ Significant improvement in psoriasis symptoms, rapid results
- ✓ Treats all skin types, areas of all ages, and any area of the body
- ✓ Most treatment sessions typically 15-20 minutes in office
- ✓ Connecting with major insurance plans

XTRAC is available in our office!

Contact Us to Learn More
000-000-0000
www.practclearx.com

TEMPLATE 4

Vitiligo Does Not Have to Be Forever

XTRAC for Vitiligo

XTRAC LIGHT THERAPY IS A SERIES OF IN-OFFICE TREATMENTS OFFERING:

- ✓ Safe, effective, in-pain-free therapy targeting the problem areas
- ✓ Most treatment sessions typically 15-20 minutes in office
- ✓ Treats all skin types, colors and areas, and any area of the body
- ✓ Connects to major insurance plans

XTRAC is available in our office!

Contact Us to Learn More
000-000-0000
www.practclearx.com

XTRAC
Drug-free treatment option for children and teens with mild to moderate psoriasis

www.practclearx.com



TheraClearX

WEBINAR REGISTRATION
TheraClearX Acne Treatment System

WEDNESDAY March 22, 2023 | TIME 7:00 PM (EST)

CLICK HERE TO REGISTER



GIRISH (GILLY) S. MUNAVALLI
MD, MCh, FRCO, FRCR

XTRAC

Take a Break from Creams & Lotions



XTRAC is an in-office treatment delivering targeted UVB light to areas of skin affected by psoriasis without the

NASDAQ: SSKN




STRATA
SKIN SCIENCES

DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics



DTC Model Driver

Core Business Refocused to DRIVE Recurring Revenue Model




Net U.S. Recurring Revenue	\$21.1M	\$23.6M	\$16.8M	\$21.2M	\$21.6M	\$20.2M
Change in US Recurring Revenue		+12%	-29%	+26%	+2%	-6%

Significant opportunity to increase ARR back to 2019 levels using proven DTC strategies that should yield appreciable incremental revenue and at higher incremental margins, allowing the Company to become cash flow positive again

International Sales Operations

Total International Install Base > 1,700 devices



- In-house Head of International Sales
- 39 international partner XTRAC® clinics (S. Korea, Japan) at 9/30/24
- Capital equipment sales preferred model
- Usage per device higher than in U.S. market
- TheraClear®X equipment sales opportunity
- Latin America & European markets untapped

XTRAC[®]: Overview



Safe, effective treatment



150+ peer-reviewed clinical studies



Psoriasis treatment is the number 1 domestic use for XTRAC[®] lasers – 80% of treatments



Opportunities exist for expanding use for other approved indications like vitiligo and eczema



Clinical support team focused on:

- In-office training
- Best practices



STRATA
SKIN SCIENCES

Indicated for Chronic Dermatological Diseases



~7.5 million
adults in the US^{1,a}



~2–3 million
adults in the US²




~16.5 million
adults in the US³

Visible skin disorders can limit healthy psychosocial development and have profoundly negative consequences on quality of life³⁻⁵

1. Armstrong AW et al. *JAMA Dermatol.* 2021;157(8):940-946. Includes people 20 years of age and older.
2. Gandhi K et al. *JAMA Dermatol.* 2022;158(1):149-60.
3. Funch J, CDC et al. *J Invest Dermatol.* 2019;139(2):559-590.
4. Eboulwakil N, Ezzedine K. *Dermatol Clin.* 2017;35(11):17-28. 5. Armstrong AW, Read C. *JAMA.* 2020;322(19):1945-1950.

Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques

Psoriasis: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches



XTRAC® Psoriasis Clinical Protocol - 6.2 treatments to PASI* 75



*PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis Tx- treatments


1. Abrouk M et al. *Psoriasis Targets Ther.* 2016;6:165-173. 2. Esmat S et al. *Dermatol Clin.* 2017;35:171-192. 3. Oh CT et al. *Lasers Surg Med.* 2016;48(6):629-637.

NASDAQ: SSKN



STRATA
SKIN SCIENCES

Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches

Vitiligo: An autoimmune condition due to a loss of melanocytes, characterized by white patches of skin losing its pigment



XTRAC® Vitiligo Clinical Protocol - >75% repigmentation in less than 20 treatments¹



Long lasting results



- ✓ No pigment loss during 2-year follow-up²
- ✓ 80% facial repigmentation retention at 3-year follow-up³

1. Shi Q et al. *Photodermatol Photoimmunol Photomed*. 2013;29(1):27-33. 2. Esposito M et al. *Clin Exp Dermatol*. 2004;29:133-137. 3. Hong SB et al. *J Korean Med Sci*. 2005;20:273-278
2. Haal S et al. *Photomed Laser Surg*. 2006; 24(5):354-357
3. Semis, Silverberg NB. *J Drugs Dermatol*. 2022;21(7):773-775.


NASDAQ: SSKN

STRATA
SKIN SCIENCES

XTRAC[®] is a Preferred Treatment for 90% of Psoriasis Patients (<10% BSA)



Source: National Psoriasis Foundation



American Academy of Dermatology Psoriasis Clinical Guideline

Has Clinical and Economic Competitive Advantage

	XTRAC®	NB-UVB	Topical Steroids	Non-Biologic Systemics	Biologics
Approximate Costs (\$)	✓ 1K-3K	3K-9K	1K-7K	1K	32K-68K
Clinical Outcomes	✓ 92%	71%	75%	48%	50-70%
Speed of Onset	✓ 5	10	3	14	12
Days of Actual Care	✓ 18	80	294	52	12-65
Remission	✓ 2.5 Months	Continued with maintenance	Continued with maintenance	Continued with maintenance	Continued with maintenance
Adverse Events	✓ Mild Temp	Mild Temp	Mild-Mod Temp – Lasting	Mild-Severe Temp – Lasting	Mild-Severe Temp – Lasting

1. Marchetti A, Bhutani T, Lockshin B, Siegel DM, Behringer F. Therapies for Psoriasis: Clinical and Economic Comparisons. J Drugs Dermatol. 2020 Nov 1;19(11):1101-1108. doi: 10.36849/JDD.2020.5510. PMID: 33196750

XTRAC® Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners

CPT Code	Description	2024 National Average Medicare Payment Rate
96920	Excimer Laser Treatment for Psoriasis (<250 sq cm)	\$152.92
96921	Excimer Laser Treatment for Psoriasis (250 - 500 sq cm)	\$167.65
96922	Excimer Laser Treatment for Psoriasis (>500 sq cm)	\$228.23
Number of Treatment/ Week	20	30
# of Weeks / Year	48	48
Total # of Treatments / Year	960	1440
Average Revenue Per Treatment	\$190	\$190
Physician Gross Revenue (Annual)	\$182,067	\$273,100

* Subject to state legislation

** Patients who are eligible to receive CPT code 10040 services are those with acne lesions such as milia, comedones, cysts, or pustules that require surgical intervention. This may include patients with severe or persistent acne that has not responded to other treatments, or those with large or painful cysts that need to be drained or removed. Determination of the appropriate usage of the CPT code is made by the treating physician.

TheraClear[®]X: Overview



Safe, effective treatment



Peer-reviewed clinical studies



Opportunities exist for expanding use for expanding the installed base to clinics using reimbursed acne surgery procedures



Clinical support team focused on:

- In-office training
- Best practices



Acne is the Most Common Skin Condition in Dermatology




- **Up to 50 Million Americans** affected annually²
- **~85%** of all adolescents experience some degree of acne from the ages of 12 to 24 years³
- **>50%** of US women experience acne in their 20s⁴
- Acne occurring in adults is increasing⁵

1. Bickers DR et al. J Am Acad Dermatol. 2006;55:490-500.
2. Tan JKL, Bhaté K. Br J Dermatol. 2015;172 (suppl 1):103-12.
3. White GM. J Am Acad Dermatol. 1998;39:334-337.
4. Collier C et al. J Am Acad Dermatol. 2008;58:54-59.
5. Holzmann R, Shakeri K. Skin Pharmacol Physiol. 2014;27 (suppl 1):3-8.

Photopneumatic Technology Combines VACUUM with PULSED BROADBAND LIGHT

- Clears bacteria and follicular contents from pilosebaceous unit, C acnes are removed both mechanically and thermally from the active acne lesion. Reduces sebum production



Baseline



After 4 tx

Addresses Limitations of Existing Acne Therapies

TheraClear®X

- ✓ Comfortable in-office treatment with no down-time
- ✓ Visible improvement of acne lesions as early as after second treatment
- ✓ Visible improvement of skin texture, pore size, and perilesional erythema after the first few treatments

Systemic and topical acne treatments

- × Are often associated with poor adherence due to forgetfulness, inconvenience, and adverse effects^{1,2}
- × Typically require 3 to 6 weeks to achieve visible improvement³
- × Can be associated with skin dryness, irritation, burning, and bleaching effects²



Treatment regimen

Initiation

4 to 6 treatments, scheduled 1-2 weeks apart

Maintenance

1 to 2 months apart as needed



Procedure

~15 minutes per treatment

No pre-treatment with topical analgesics

Comfortable with **no down time**

Can be **delegated** (depending on state laws)



Time to improvement

Visible improvement of acne lesions **as early as after second treatment**

Visible improvement of skin texture, pore size, and perilesional erythema **after the first few treatments**

1. Snyder S et al. Am J Clin Dermatol. 2014;15(2):87-94. 2. Tuohy J M et al. Patient Pref Adherence. 2016;10:2091-2096. 3. Fox L et al. Molecules. 2016;21:1063. doi:10.3390/molecules21081063. 4. Data on file. STRATA Skin Sciences.

TheraClear®X Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners

CPT Code	Description	2024 National Average Medicare Payment Rate
10040	Acne Surgery, which Involves the opening or removal of multiple milia, comedones, cysts and pustules.	\$114.61

Number of Treatment/ Week	20	30
# of Weeks / Year	48	48
Total # of Treatments / Year	960	1,440
Average Revenue Per Treatment	\$114.61	\$114.61
Physician Gross Revenue (Annual)	\$110,025.60	\$165,038.40

* Subject to state legislation

** Patients who are eligible to receive CPT code 10040 services are those with acne lesions such as milia, comedones, cysts, or pustules that require surgical intervention. This may include patients with severe or persistent acne that has not responded to other treatments, or those with large or painful cysts that need to be drained or removed. Determination of the appropriate usage of the CPT code is made by the treating physician.

SUMMARY

Financial Metrics

(All numbers below in \$'000s except for U.S. Installed Base)

	2019	2020	2021	2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	FY 2023	Q1 2024	Q2 2024	Q3 2024
U.S. Gross Recurring Revenue	\$24,590	\$16,901	\$22,071	\$22,271	\$4,735	\$5,057	\$4,883	\$4,947	\$19,622	\$4,578	\$4,735	\$4,799
U.S. Installed Base (XTRAC® Devices)	820	832	890	909	916	930	929	923	923	907	882	873
Average Gross Recurring Revenue/device/Qtr	\$7,497	\$5,078	\$6,200	\$6,125	\$5,169	\$5,438	\$5,256	\$5,360	\$5,315	\$5,047	\$5,369	\$5,497
Revenues, net	\$31,586	\$23,090	\$29,977	\$36,161	\$7,567	\$8,250	\$8,852	\$8,689	\$33,358	\$6,754	\$8,435	\$8,797
Cost of revenues	11,316	8,956	10,127	14,393	3,179	3,932	3,898	3,888	14,897	3,674	3,498	3,490
Gross profit	20,270	14,134	19,850	21,768	4,388	4,318	4,954	4,801	18,461	3,080	4,937	5,307
Operating expenses:												
Engineering and product development	1,002	1,274	1,434	1,029	315	374	248	380	1,317	241	199	243
Selling and marketing	12,003	9,038	13,106	15,301	3,742	3,416	3,038	2,760	12,956	3,018	3,014	3,048
General and administrative	10,275	7,898	9,712	10,087	2,917	2,490	2,283	2,818	10,508	2,710	2,210	1,888
Impairment of goodwill	-	-	-	-	-	-	-	2,284	2,284	5,969	-	-
Total Expenses	\$23,280	\$18,210	\$24,252	\$26,417	\$6,974	\$6,280	\$5,569	\$8,242	\$27,065	\$11,938	\$5,423	\$5,179
Loss from operations	(\$3,010)	(\$4,076)	(\$4,402)	(\$4,649)	(\$2,586)	(\$1,962)	(\$615)	(\$3,441)	(\$8,604)	(\$2,889)	(\$486)	\$128
Non-GAAP adjusted EBITDA	\$3,036	\$1,492	\$1,467	\$2,557	(\$759)	(\$95)	\$1,291	\$520	\$957	(\$1,279)	\$1,012	\$1,493
Net cash provided (used) by operating activities	\$2,229	\$2,096	\$1,508	(\$924)	(\$1,203)	\$175	\$(997)	\$1,506	(\$519)	(\$804)	\$591	(\$515)

STRATA Investment Summary

Unique and Proven Business Model

- Best-in-class Excimer Laser technologies
- Recurring revenue driven by DTC and growing installed base
 - Installed base of 873 XTRAC® domestic devices for Psoriasis, Vitiligo, and Eczema treatments
 - Installed base of 135 TheraClear®X domestic devices for Acne treatments
 - Installed base of ~1700 XTRAC® and VTRAC® devices internationally
- Providing “business in a box” for dermatology practices without an upfront capital spend by practices
- Over 300 peer-reviewed, published clinical studies

A Win-Win-Win Business Model

- For patients – safest, most effective, minimal side effects
- For clinics – stable increased revenue base
- For Payers – the cheapest treatment available

Opportunity for Renewed Growth in U.S. in Recurring Revenue per Device

- Re-emphasis on DTC marketing in U.S. with near-term opportunity of increasing recurring revenue/device by 40%
- More rigorous sales and marketing strategy and process in place
- Both initiatives could collectively grow revenue by double digit percent and help return the company to positive cash flow



THANK YOU!

Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com

STRATA
SKIN SCIENCES

www.strataskin.com

APPENDIX

STRATA
SKIN SCIENCES

Acquisitions to Drive Top-line Growth



January 2022


- \$1M Acquisition
- Adds attractive business segment to address \$5.5B acne market



August 2021

- \$3.7M Acquisition
- Minimal acquisition cost compared to exclusivity in external laser market

Domestic XTRAC® Installed Base Growth Drivers



As of 9/30/2024

Over 250 comeback opportunities of existing excimer laser owners

Signed strategic expansion into group clinic rollups

Within the 48 groups:

- 61 TheraClear®X devices
- Penetration grew from 86 in 2018 to 386 in 2023
- Group partnership accounts represent 37% of XTRAC® domestic recurring revenue


Increased penetration into facility locations (e.g. Kaiser, VA, and Mt. Sinai)

Representative PE Backed Groups:




Example – NYC Metro Area XTRAC[®] Placements and DTC Leads (1Q24)

Metro NYC XTRAC[®] installed base



Metro NYC 1Q24 DTC Patient Leads



Psoriasis Case Study: Patient I.B., Lewisburg, PA



37

Treatment Room



Before



After



NASDAQ: SSKN

STRATA
SKIN SCIENCES